Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05109494 · ClinicalTrials.gov registry record · Phase 2

Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas

A Phase 2 study of Soft Tissue Sarcoma, sponsored by University of Wisconsin, Madison.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT05109494: Recruiting Phase 2 study of Soft Tissue Sarcoma, sponsored by University of Wisconsin, Madison.

NCT05109494 is a Phase 2 study of Soft Tissue Sarcoma that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 30 participants, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05109494, a Phase 2 study of Soft Tissue Sarcoma, is actively recruiting participants, sponsored by University of Wisconsin, Madison.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This research study is designed to find out if radiation therapy treatment prior to surgery is safe and effective to treat soft tissue sarcomas. 30 participants with soft tissue sarcoma will be enrolled and can expect to be on study for up to 5 years.

Conditions Studied

Soft Tissue Sarcoma

Interventions

  • RADIATION Conventional Fractionated
  • RADIATION Hypofractionated

Study Locations (1)

Wisconsin

  • University of Wisconsin Hospital and Clinics - Madison

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-04-06
Est. Completion 2028-11
Phase Phase 2
University of Wisconsin, Madison

1,039 total trials

What NCT05109494 shows while recruiting

NCT05109494 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (62% lower).

The record links to 1 condition, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Conventional Fractionated is the first listed.

NCT05109494 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT05109494 about?

NCT05109494 is a clinical study titled "Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas". This research study is designed to find out if radiation therapy treatment prior to surgery is safe and effective to treat soft tissue sarcomas. 30 participants with soft tissue sarcoma will be enrolled and can expect to be on study for up to 5 years.

What is the current status of trial NCT05109494?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-04-06. Estimated completion is 2028-11.

What conditions does trial NCT05109494 study?

This clinical trial studies the following conditions: Soft Tissue Sarcoma.

What interventions are being tested in trial NCT05109494?

The interventions under investigation include: Conventional Fractionated (RADIATION), Hypofractionated (RADIATION).

Who is sponsoring clinical trial NCT05109494?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05109494 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Soft Tissue Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05109494's enrollment target sits among peer trials

30 34th of 55 higher than 17 of 55 other Soft Tissue Sarcoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05109494

Source: ClinicalTrials.gov NCT05109494, the US trial registry maintained by the National Library of Medicine. NCT05109494 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.